Arrowhead Pharmaceuticals Receives Marketing Authorization in the European Union for REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)
Go back to Arrowhead Pharmaceuticals Receives Marketing Authorization in the European Union for REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)| ARROWHEAD RESEARCH (NASDAQ: ARWR) | Delayed: 68.16 +1.68 (2.53%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $66.48 | 52 Week High | $8.22 | |||
| Open | $67.46 | 52 Week Low | $3.07 | |||
| Day High | $68.62 | P/E | N/A | |||
| Day Low | $66.06 | EPS | $-1.30 | |||
| Volume | 1,343,827 | |||||
